Anti-MOG encephalitis mimicking small vessel CNS vasculitis
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 16, 2018
- Accepted in final form October 19, 2018
- First Published February 1, 2019.
Author Disclosures
- Kristina Patterson, MD, PhD,
- Estibaliz Iglesias, MD, PhD,
- Maclean Nasrallah, MD, PhD,
- Verónica González-Álvarez, MD,
- Mariona Suñol, MD,
- Jordi Anton, MD, PhD,
- Albert Saiz, MD, PhD,
- Eric Lancaster, MD, PhD and
- Thaís Armangue, MD, PhD
- Kristina Patterson, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NINDS R25 NS065745, trainee, 2.0 years
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Estibaliz Iglesias, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maclean Nasrallah, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Verónica González-Álvarez, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mariona Suñol, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jordi Anton, MD, PhD,
Scientific advisory board for Novartis, Sobi, Gebro
NONE
Abbvie, Roche, Pfizer, Sobi, Gebror
NONE
NONE
NONE
NONE
NONE
Abbvie, Pfizer, Roche, Gebro,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Albert Saiz, MD, PhD,
NONE
NONE
compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd, Novartis, and Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eric Lancaster, MD, PhD and
(1) Advisory board for Grifols (2) Advisory board for Amgen (3) Advisory board for Janssen
NONE
(1) Grifols Inc. Honoraria for teaching in courses to train their sales team about CIDP, and honoraria/travel to give a talk at the Peripheral nerve society meeting.
NONE
NONE
NONE
NONE
(1) Medimmune Inc., fees for expert consultation. (2) Merck Inc., fees for medical-legal consultation. (3) Novartis Inc., fees for expert consultation.
NONE
(1) Federal Vaccine Injury Compensation Program. Fees for expert review of cases.
NONE
(1) Grifols Inc. Investigator Sponsored Grant,
(1) NINDS, K08 NS075142, PI, 2013-2017.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Rogers Towers PA, 2015, medical legal consultation. (2) Orlando Health, 2015, medical legal consultation. (3) Wilson, Elser, Moskowitz, Edelman & Dicker LLP, medical legal consultation.
- Thaís Armangue, MD, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research was supported in part by Mutua Madrile?a Fundation AP162572016
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neurology Department (K.P., E.L.), University of Pennsylvania, Philadelphia; Rheumatology Department, Sant Joan de Deu Children's Hospital (E.I., J.A.), University of Barcelona, Spain; Department of Pathology (M.N.), University of Pennsylvania, Philadelphia; Pediatric Neuroimmunology Unit (V.G.-Á., T.A.), Sant Joan de Déu Children's Hospital, University of Barcelona, Spain; Department of Pathology (M.S.), Sant Joan de Déu Children's Hospital, University of Barcelona, Spain; and Neuroimmunology Program (A.S., T.A.), IDIBAPS-Hospital Clinic, University of Barcelona, Spain.
- Correspondence
Dr. Armangue armangue{at}clinic.cat
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Nicole Sur and Dr. Mausaminben Hathidara
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Editorial
Diagnostic challenges and pitfalls of myelin oligodendrocyte glycoprotein antibody–associated demyelinationLessons from neuropathologyRomana Höftberger, Ellen Gelpi et al.Neurology: Neuroimmunology & Neuroinflammation, February 01, 2019 -
Article
Differential diagnosis and evaluation in pediatric inflammatory demyelinating disordersKevin Rostasy, Barbara Bajer-Kornek, Sunita Venkateswaran et al.Neurology, August 29, 2016 -
What's Happening
What's happening in Neurology® Neuroimmunology & Neuroinflammationet al.Neurology, July 22, 2019 -
Editor's Corner
Rectifying neurologic diagnosis through autoantibodiesJosep Dalmau et al.Neurology: Neuroimmunology & Neuroinflammation, February 15, 2019